Patrick J. Crutcher - 16 Jul 2026 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Director
Issuer ticker: JSPR
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jul 2026, 20:38:57 UTC
Prior SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Crutcher

Key filing fact

Patrick J. Crutcher filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 20 Jul 2026.

Key facts

This page summarizes Patrick J. Crutcher's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Jul 2026, 20:38.

Change

Previous filing in this sequence was filed on 19 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001754540 Primary reporting owner

Crutcher Patrick J

Relationship: Director
Address: C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PKWY, SUITE #102, REDWOOD CITY
Signature: /s/ Patrick J. Crutcher
Signature date: 20 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Stock Option (Right to Buy

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 15,000
Exercise price: $0.7740
Footnotes: F1

JSPR transaction Derivative

Non-Voting Convertible Preferred Stock

Purchase

Transaction value
Shares: +888
Change %
Price
Shares after: 888
Date: 20 Jul 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 888
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date.

Footnote F2

On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.

Footnote F3

On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.